---
schema_version: "secwatch.filing_event.v1"
accession: "0001831283-22-000059"
form_type: "8-K"
ticker: "LIANY"
cik: "0001831283"
company_name: "LianBio"
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T01:05:34.448600+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# LianBio Q2 net loss $42.4M; cash $349.4M; mavacamten China Phase 3 enrollment complete

## Summary
- Net loss of $42.4M in Q2 2022 vs. $100.4M loss in Q2 2021; R&D expenses fell to $28.6M.
- Cash balance $349.4M at June 30, 2022; runway projected into second half of 2024.
- Completed enrollment in China Phase 3 EXPLORER-CN trial of mavacamten; topline data mid-2023.
- Submitted NDAs: mavacamten in Singapore (oHCM) and infigratinib in Hong Kong (cholangiocarcinoma).
- Three additional registration-enabling programs (TP-03, NBTXR3, BBP-398) to begin in China by year-end 2022.

## SEC filing metadata
- accession: 0001831283-22-000059
- form_type: 8-K
- ticker: LIANY
- cik: 0001831283
- company_name: LianBio
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831283/000183128322000059/0001831283-22-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831283/000183128322000059/lian-20220811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001831283-22-000059
- JSON: https://secwatch.observer/filing/0001831283-22-000059.json
- Plain text: https://secwatch.observer/filing/0001831283-22-000059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.